

## **Supplementary materials**

### **Supplementary Fig. 1**

The TCGA data (<https://cancergenome.nih.gov/>) were processed to evaluate the expression of lncRNA SAP30L-AS1 and SChLAP1 in 499 PCa patients and 52 adjacent non-cancer tissues. (A). and (B). SAP30L-AS1 and SChLAP1 levels in the tumor tissues were significantly higher than these levels in the non-tumor tissues.

### **Supplementary Fig. 2**

Receiver operating characteristic (ROC) curves of BPH. (A). and (B). The diagnostic value of SChLAP1 is better than SAP30L-AS1 to differentiate BPH patients from the controls. (C). The area of the combination of two lncRNA was equal to 0.935; (D). and (E). Two lncRNA separately combined with PSA possessed a moderate ability for discrimination. (F). The AUC of two lncRNAs combined with PSA was 0.986.

## Supplementary Table1


### The basic information of PCa patients, BPH patients and healthy controls.

	30 healthy controls	46 Benign Prostatic Hyperplasia		34 Prostate Cancer	
	Median (range)	Median (range)	P value	Median (range)	P value
Age(year)	69 (62-81)	70 (53-89)	0.535	73 (56-86)	0.064
PSA(ng/mL)					
Total	1.44 (0.37-3.66)	6.66 (0.29-30.8)	< 0.0001	68 (0.20-268)	< 0.0001
≤10	30	37	< 0.0001	13	< 0.0001
>10	-	9	-	21	-
Unknown	-	-	-	-	-
Gleason sum					
<7	-	-	-	5	-
7	-	-	-	12	-
3+4	-	-	-	7	-
4+3	-	-	-	5	-
>7	-	-	-	13	-
Unknown	-	-	-	4	-
pT-stage					
T2	-	-	-	11	-
T3a	-	-	-	2	-
T3b	-	-	-	6	-
T4	-	-	-	6	-
Unknown	-	-	-	9	-
Lymph node metastasis					
Yes	-	-	-	9	-
No	-	-	-	17	-
Unknown	-	-	-	8	-
Development					


of metastasis

Yes	-	-	-	14	-
No	-	-	-	12	-
Unknown	-	-	-	8	-

---



Supplementary Fig. 1



Supplementary Fig. 2